On September 27th, 2024, the FDA approved Sanofi/Regeneron's Dupixent® (dupilumab) for use as an add-on maintenance treatment of adults who have inadequately controlled chronic obstructive pulmonary disease (COPD) and eosinophilic phenotype. In clinical trials, Dupixent significantly reduced COPD exacerbations by 34% as compared to placebo. This approval makes dupilumab the first biological treatment for COPD. ProAct recommends the use of prior authorization on all specialty medications to ensure patients have tried and failed lower cost alternatives.
https://www.ajmc.com/view/fda-approves-dupilumab-as-first-biologic-treatment-for-copd?utm_content=310319519&utm_medium=social&utm_source=linkedin&hss_channel=lcp-2029474
